대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	CARDIOVASCULAR STRATIFICATION BY PLASMA SCLEROSTIN IN DIALYSIS PATIENTS
저자	Kyubok Jin* 1, 2, Hayeon Park1, 2, Yaerim Kim1, 2, Sang Mok Yeo1, 2, Seong Sik Kang1, 2, Woo Yeong Park1, 2, Seungyeup Han1, 2, Sihyung Park3, Bongsoo Park3, Yang-Wook Kim3, Sung Bae Park1, 2
출판정보	2016; 2016(1):
키워드	Sclerostin, Peripheral vascular calcification, Cardiovascular events, ESRD patients
초록	Background: Vascular calcification, which is caused by Wnt pathway, is related to cardiovascular mortality in dialysis patients. A sclerostin is known to be an endogenous antagonist of bone calcification with Wnt pathway. However, its roles and meanings in vascular calcification are unclear. This study tested the hypothesis that increased plasma sclerostin is related with coronary arterial calcification score (CCS) in dialysis patients. Methods: Sclerostin, hsCRP, lipid levels, calcium, phosphate, and iPTH levels were measured in the fasting plasma samples from 20 hemodialysis and 20 peritoneal dialysis patients, and 20 healthy and- and gender-matched controls. CCSs were measured by the coronary computed tomography angiogram. Cardiovascular risk was assumed by CCS (0; non-identified, 1~10; minimal, 1~100; mild, 101~400; moderate, >400; high). Results: Plasma sclerostin concentrations in the hemodialysis (6.06 ± 3.10 ng/mL) and peritoneal dialysis (5.28 ± 3.20 ng/mL) groups were significantly higher than that in the control group (0.91 ± 0.19 ng/mL). CCS in the hemodialysis (1112.2 ± 385.6) was significantly higher than those in the peritoneal dialysis (414.9 ± 129.4) and control group (5.98 ± 4.04). Both sclerostin and CCS were increased according to the dialysis vintage (r = 0.759 and r = 0.662, p < 0.001). The level of plasma sclerostin was related to CCS (r = 0.657, p < 0.001) even controlling for age, sex, dialysis vintage and levels of blood sugar, phosphate, calcium. Conclusion: In our cohort of dialysis patients, higher level of sclerostin showed higher burden of coronary calcification and therefore sclerostin might be a candidate biomarker for cardiovascular risk assessment in dialysis patients.
원문(PDF)	PDF 원문보기

목록

위로가기